117 related articles for article (PubMed ID: 31515294)
1. Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy.
Helms MW; Jahn-Hofmann K; Gnerlich F; Metz-Weidmann C; Braun M; Dietert G; Scherer P; Grandien K; Theilhaber J; Cao H; Wagenaar TR; Schnurr MM; Endres S; Wiederschain D; Scheidler S; Rothenfußer S; Brunner B; König LM
Mol Cancer Ther; 2019 Dec; 18(12):2343-2356. PubMed ID: 31515294
[TBL] [Abstract][Full Text] [Related]
2. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier J; Wei J; Duewell P; Hoves S; Stieg MR; Adunka T; Noerenberg D; Anders HJ; Mayr D; Poeck H; Hartmann G; Endres S; Schnurr M
Cancer Res; 2013 Mar; 73(6):1709-20. PubMed ID: 23338611
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.
Meng G; Xia M; Xu C; Yuan D; Schnurr M; Wei J
Int J Cancer; 2014 Apr; 134(8):1958-71. PubMed ID: 23921958
[TBL] [Abstract][Full Text] [Related]
5. Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling.
Peng D; Chen L; Sun Y; Sun L; Yin Q; Deng S; Niu L; Lou F; Wang Z; Xu Z; Wang C; Fan L; Wang H; Wang H
Biomed Pharmacother; 2020 May; 125():109984. PubMed ID: 32066042
[TBL] [Abstract][Full Text] [Related]
6. An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation.
Castiello L; Zevini A; Vulpis E; Muscolini M; Ferrari M; Palermo E; Peruzzi G; Krapp C; Jakobsen M; Olagnier D; Zingoni A; Santoni A; Hiscott J
Cancer Immunol Immunother; 2019 Sep; 68(9):1479-1492. PubMed ID: 31463653
[TBL] [Abstract][Full Text] [Related]
7. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
[TBL] [Abstract][Full Text] [Related]
8. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract][Full Text] [Related]
9. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
[TBL] [Abstract][Full Text] [Related]
10. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
[TBL] [Abstract][Full Text] [Related]
11. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.
Poeck H; Besch R; Maihoefer C; Renn M; Tormo D; Morskaya SS; Kirschnek S; Gaffal E; Landsberg J; Hellmuth J; Schmidt A; Anz D; Bscheider M; Schwerd T; Berking C; Bourquin C; Kalinke U; Kremmer E; Kato H; Akira S; Meyers R; Häcker G; Neuenhahn M; Busch D; Ruland J; Rothenfusser S; Prinz M; Hornung V; Endres S; Tüting T; Hartmann G
Nat Med; 2008 Nov; 14(11):1256-63. PubMed ID: 18978796
[TBL] [Abstract][Full Text] [Related]
12. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
13. Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists.
Chiang C; Beljanski V; Yin K; Olagnier D; Ben Yebdri F; Steel C; Goulet ML; DeFilippis VR; Streblow DN; Haddad EK; Trautmann L; Ross T; Lin R; Hiscott J
J Virol; 2015 Aug; 89(15):8011-25. PubMed ID: 26018150
[TBL] [Abstract][Full Text] [Related]
14. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
15. A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.
Matheis F; Heppt MV; Graf SA; Düwell P; Kammerbauer C; Aigner A; Besch R; Berking C
J Invest Dermatol; 2016 Dec; 136(12):2475-2484. PubMed ID: 27498344
[TBL] [Abstract][Full Text] [Related]
16. 5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice.
Han Q; Hou Z; Yin C; Zhang C; Zhang J
Antiviral Res; 2019 Jan; 161():36-45. PubMed ID: 30448255
[TBL] [Abstract][Full Text] [Related]
17. Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy.
Peng B; Nguyen TM; Jayasinghe MK; Gao C; Pham TT; Vu LT; Yeo EYM; Yap G; Wang L; Goh BC; Tam WL; Luo D; Le MT
J Extracell Vesicles; 2022 Apr; 11(4):e12187. PubMed ID: 35430766
[TBL] [Abstract][Full Text] [Related]
18. The autoinhibitory CARD2-Hel2i Interface of RIG-I governs RNA selection.
Ramanathan A; Devarkar SC; Jiang F; Miller MT; Khan AG; Marcotrigiano J; Patel SS
Nucleic Acids Res; 2016 Jan; 44(2):896-909. PubMed ID: 26612866
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of duplex RNA harboring 5'-terminal triphosphate on gene silencing and RIG-I mediated innate immune response.
Baek SE; Kim H; Kim KB; Yoon S; Choe J; Suh W; Jeong YJ; Cho YH; Kim DE
Biochem Biophys Res Commun; 2015 Jan; 456(2):591-7. PubMed ID: 25490387
[TBL] [Abstract][Full Text] [Related]
20. RIG-I activation is critical for responsiveness to checkpoint blockade.
Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
